You’ve hit your goal weight. Or your insurance changed. Or you’re just tired of paying every month for a drug you assumed was temporary.
Whatever the reason, you’re thinking about stopping the GLP-1 drug you’re taking.
Before you do, answer these six questions. The people who come off these drugs successfully tend to have answers. The people who struggle usually don’t.
And what we know about stopping changed a few months ago.
For two years the story was brutal and simple: Quit these drugs, gain it all back. That came straight from the trials.
In the STEP 1 extension study, people who stopped semaglutide regained about two-thirds of their loss within a year. In the SURMOUNT-4 study, only 17% of those who quit tirzepatide kept off at least 80% of what they’d lost.
Then in March, Cleveland Clinic published something different.
Researchers tracked nearly 8,000 real patients in Ohio and Florida who started semaglutide or tirzepatide, then stopped within a year. Those treated for obesity had lost 8.4% of their body weight. Twelve months after quitting, they’d regained an average of only 0.5%.
About 20% of those patients restarted the original drug. Another 35% moved to a different treatment. In other words, more than half weren’t really off anything — they just swapped.
That’s the whole ballgame, and it’s why these questions matter.
1. Why are you really quitting?
Three answers are common, and they lead three different directions.
- Cost. This is the most solvable it’s ever been, and I’ll get to it in a second.
- Side effects. That’s often a dose conversation, or a switch to a different drug. Not necessarily a full stop.
- “I hit my goal, so I’m done.” This one deserves the hardest look. Obesity medicine doesn’t treat weight the way most of us do. It treats it as a chronic condition, like high blood pressure. Nobody hits a blood pressure target and throws away the pills.
Be honest about which camp you’re in. The answer changes everything that follows.
2. What would staying on actually cost you?
The math looks different than it did a year ago.
If you’re on Medicare, it’s very different. As of July 1, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, which gets eligible Part D enrollees Wegovy, the Zepbound KwikPen or Foundayo for a flat $50 monthly copay.
Eligibility is tight. You needed a body mass indes, or BMI, of 35 or higher when you started therapy, or 27-plus with a qualifying condition like prediabetes, a prior heart attack or a stroke. I walked through the details in “7 Catches in Medicare’s New $50 Weight-Loss Drug Deal.”
Not on Medicare? List prices still run north of $1,000 a month. But manufacturer direct-pay programs have knocked that down to a few hundred for a lot of people.
NBC News reported that monthly prices through TrumpRx are expected to start around $350 and drift toward $250 within two years.
Run your own number before you quit. As I explained in “The $4,200 Ozempic Ransom You Have to Pay Every Year to Keep the Weight Off,” the annual figure is what stings. But “too expensive” may have been true in 2024 and flat wrong today.
3. Is somebody else about to make this call for you?
The Medicare Bridge is temporary. It runs through Dec. 31, 2027, and nobody has committed to what replaces it. CMS also says plainly that there’s no appeals process under the Bridge. If your prior authorization gets denied, there’s no second bite at the apple.
Part D formularies shift constantly, too, which we covered in “Retirees, Beware: Medicare Won’t Pay for These Drugs in 2026.”
On the commercial side, employers are backing away. A Business Group on Health survey of large employers found 67% currently cover GLP-1s for weight management — but only about 72% of those said they’d likely keep covering them in 2027.
A job change or a formulary update can end this on somebody else’s schedule. And if you’re counting on COBRA to bridge a gap, read “Leaving Your Job? 7 Hard Truths About COBRA” first — it’s rarely the cheap safety net people assume.
Far better to plan your exit than have one handed to you.
One thing before we keep going — the financial world is louder and dumber than ever. Hot takes everywhere. Almost none of it is worth your time. I’ve spent 35+ years cutting through the noise so you don’t have to. Sign up for the free Money Talks Newsletter — 10 seconds, no spam, just the stuff that matters.
4. Have you asked about tapering instead of stopping?
Honest answer: Nobody’s nailed down the right way to do this yet.
The Obesity Association’s own best-practice guidance says it out loud — the optimal schedule for tapering off these medications remains poorly defined, and so does the question of who can maintain their loss afterward.
What some clinicians do in practice is step the dose down gradually instead of stopping cold, or they park patients at the lowest effective dose indefinitely.
Whether either fits you is a conversation with your prescriber. It’s absolutely not something to wing on your own with leftover pens.
5. What’s your plan B?
Go back to that Cleveland Clinic study for a minute.
The patients who held their weight weren’t white-knuckling it. Most had something next — a restart, a different medication, ongoing clinical support.
Lead researcher Hamlet Gasoyan said real-world patients regained less than trial patients partly because so many restarted or transitioned to another obesity treatment.
So, “I’ll stop and just eat better” isn’t a plan. It’s a wish.
A plan has a name, a follow-up appointment, goals and a date on the calendar.
6. What did you lose besides fat?
Almost nobody asks this one. I’d want it answered before I quit anything.
Fast weight loss takes muscle along with fat. Published reviews of GLP-1 trials put lean mass at roughly 20% to 30% of total weight lost.
That’s not unique to these drugs. It happens with any rapid loss. But the absolute numbers are bigger here, because the losses are bigger.
Now here’s the part that should get your attention.
What you lose is a mix of fat and muscle. What you regain tends to be mostly fat.
Quit without a strategy and you can land back at your old weight with worse body composition than when you started. Same number on the scale, weaker body underneath.
Talk to your doctor about resistance training and protein before you stop, not after.
The bottom line
These drugs work as long as you take them. That’s not a scandal. It’s how they work, same as statins or blood pressure medication.
So the real decision was never “should I stop?”
It’s “what am I doing instead, and can I afford to keep doing it?”
Answer those six questions honestly. Then go have the conversation with your doctor.
Add a Comment